Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M MOSKOWITZ

Showing results (221-230 of 234) with videos related to

Pageof 24
Sort By:
Cold Spring Harbor Molecular Case Studies|September 15, 2016
A de novo missense mutation in ZMYND11 is associated with global developmental delay, seizures, and hypotoniaAbby M Moskowitz, Newell Belnap, Ashley L Siniard, et al.
ACS Infectious Diseases|July 12, 2017
Investigating the Interaction of Octapeptin A3 with Model Bacterial MembranesMei-Ling Han, Hsin-Hui Shen, Karl A Hansford, et al.
The New England Journal of Medicine|October 19, 2018
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del AllelesDominic Keating, Gautham Marigowda, Lucy Burr, et al.
International Journal of Environmental Research and Public Health|April 13, 2023
Cell Phone Radiation Exposure Limits and Engineering SolutionsPaul Héroux, Igor Belyaev, Kent Chamberlin, et al.
The New England Journal of Medicine|November 8, 2019
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del AllelePeter G Middleton, Marcus A Mall, Pavel Dřevínek, et al.
The New England Journal of Medicine|October 19, 2018
VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del AllelesJane C Davies, Samuel M Moskowitz, Cynthia Brown, et al.
Lancet (London, England)|November 5, 2019
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trialHarry G M Heijerman, Edward F McKone, Damian G Downey, et al.
The New England Journal of Medicine|August 26, 2021
Triple Therapy for Cystic Fibrosis <i>Phe508del</i>-Gating and -Residual Function GenotypesPeter J Barry, Marcus A Mall, Antonio Álvarez, et al.
American Journal of Respiratory and Critical Care Medicine|March 18, 2021
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One <i>F508del</i> AlleleEdith T Zemanick, Jennifer L Taylor-Cousar, Jane Davies, et al.
The European Respiratory Journal|November 9, 2023
Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one <i>F508del</i> allele: 144-week interim results from a 192-week open-label extension studyCori L Daines, Elizabeth Tullis, Stefano Costa, et al.
Pageof 24

Showing results (221-230 of 234) with videos related to

Sort By:
Pageof 24
Cold Spring Harbor Molecular Case Studies|September 15, 2016
A de novo missense mutation in ZMYND11 is associated with global developmental delay, seizures, and hypotoniaAbby M Moskowitz, Newell Belnap, Ashley L Siniard, et al.
ACS Infectious Diseases|July 12, 2017
Investigating the Interaction of Octapeptin A3 with Model Bacterial MembranesMei-Ling Han, Hsin-Hui Shen, Karl A Hansford, et al.
The New England Journal of Medicine|October 19, 2018
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del AllelesDominic Keating, Gautham Marigowda, Lucy Burr, et al.
International Journal of Environmental Research and Public Health|April 13, 2023
Cell Phone Radiation Exposure Limits and Engineering SolutionsPaul Héroux, Igor Belyaev, Kent Chamberlin, et al.
The New England Journal of Medicine|November 8, 2019
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del AllelePeter G Middleton, Marcus A Mall, Pavel Dřevínek, et al.
The New England Journal of Medicine|October 19, 2018
VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del AllelesJane C Davies, Samuel M Moskowitz, Cynthia Brown, et al.
Lancet (London, England)|November 5, 2019
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trialHarry G M Heijerman, Edward F McKone, Damian G Downey, et al.
The New England Journal of Medicine|August 26, 2021
Triple Therapy for Cystic Fibrosis <i>Phe508del</i>-Gating and -Residual Function GenotypesPeter J Barry, Marcus A Mall, Antonio Álvarez, et al.
American Journal of Respiratory and Critical Care Medicine|March 18, 2021
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One <i>F508del</i> AlleleEdith T Zemanick, Jennifer L Taylor-Cousar, Jane Davies, et al.
The European Respiratory Journal|November 9, 2023
Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one <i>F508del</i> allele: 144-week interim results from a 192-week open-label extension studyCori L Daines, Elizabeth Tullis, Stefano Costa, et al.
Pageof 24